Johnson & Johnson JNJ

$263.73 +2.29 (0.88%)

Valuation

Market cap
630,043,712,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
23.62
Forward PE
22.95
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
5,905,000
Avg volume
6,548,144
Day's range
$260.37 – $264.39
Shares out
2,409,898,000
Stochastic %K
73%
Beta
0.21
Analysts
Strong Sell
Price target
$282.76

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

cubie Oct 13, 3:04 PM
$JNJ bcearnings showed it does not justify the valuation
0 replies
briefingcom Oct 13, 2:52 PM
$JNJ: Johnson & Johnson is sharply lower despite a Q3 earnings beat, as sluggish MedTech growth and a modest guidance increase overshadow strong pharmaceutical sales. Newer therapies are gaining traction, but pipeline spending and questions around a potential orthopedics spinoff cloud the outlook. https://www.briefing.com/story-stocks/archive/2026/10/13/johnson--and--johnson-down-sharply-as-medtech-weakness-overshadows-drug-growth-higher-guidance-(jnj)?utm_campaign=storystocks&utm_medium=social&utm_source=st&utm_content=link #Earnings #Healthcare #Pharma #MedTech
0 replies
itsphd Oct 13, 2:38 PM
$JNJ so why did this fall?
0 replies
OptionRunners Oct 13, 2:32 PM
$JNJ dip buyer stepping in with these calls on the earnings drop
0 replies
chursinow62 Oct 13, 2:30 PM
$JNJ Going to fall back to $240
0 replies
Marketlogik Oct 13, 2:24 PM
$JNJ price action should make sense fondamentals lean bullish
0 replies
alphagenhq Oct 13, 2:19 PM
$JNJ Adj EPS $2.59 vs $2.54 est. Revenue $25.4B vs $25.28B est. Adjusted EPS guidance moved up to a $11.10 midpoint. GAAP EPS was only $0.09 because of a one-time talc settlement charge plus M&A costs, so don't let that headline scare you. Pharma did the heavy lifting: Tremfya sales rose 68% to $2.4B. The soft spots were Medtech, up just 2.5% and short of the $8.71B estimate, and Darzalex at $4.24B vs $4.4B expected.
0 replies
GreedWorks Oct 13, 2:13 PM
$JNJ stock reaction..one word...criminal
0 replies